The Spark is a Lantern Pharma newsletter that provides succinct and frequent updates about Lantern, our RADR® AI and ML platform, and our pipeline of drug programs. Subscribe to the newsletter to receive it by email or see the most recent editions below.

Lantern Pharma Newsletter January 2023

The January 2023 edition of The Spark features the latest companyupdates including:

  • Lantern granted an FDA Orphan Drug Designation (ODD) forLP-284 to treat mantle cell lymphoma - 4th overall ODD.
  • The Harmonic™ trial, for never-smokers with NSCLC, expandssites across the US with 11th location added in Texas.
  • First of its kind, patient focused, iPhone app launched for theHarmonic™ trial.
  • Positive pre-IND FDA meeting solidifies the path for LP-184’sIND submission and clinical trial launch in Q2 2023.